Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options

This is the first study in patients of F901318. Patients with a limited treatment options
will be enrolled and treated with F901318 (olorofim) for up to 12 weeks.

Inclusion Criteria:

- Male and female aged 18 or older whom have given informed consent

- Ability to comply with the protocol

- Females must be non lactating and not at risk of pregnancy

- Patients with invasive fungal disease

- Patients who have limited alternative treatment options

Exclusion Criteria:

- Women who are pregnant or breast feeding

- Known history of allergy hypersensitivity to any study drug components

- Patients with chronic aspergillosis

- HIV patients who are not receiving antiretroviral therapy

- Previously enrolled patients or patients enrolled in any clinical trial within the
last 30 days

- Patients with a medical condition that may jeopardize adherence to the protocol or may
cause unacceptable additional risk to the patient

- Patients with predicted short survival time

- Prohibited concomitant medications